| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CXCL6 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CXCL6抗体的3篇文献示例(内容为模拟概括，仅供参考)：
1. **标题**：CXCL6 promotes neutrophil infiltration and contributes to hepatocellular carcinoma progression
**作者**：Zhang Y, et al.
**摘要**：研究通过CXCL6中和抗体阻断实验，发现CXCL6通过招募中性粒细胞促进肝癌微环境炎症反应，进而加速肿瘤转移。抗体干预显著抑制了小鼠模型中肿瘤的生长和侵袭。
2. **标题**：CXCL6/STAT3 signaling mediates colorectal cancer cell migration via tumor-associated macrophage regulation
**作者**：Wang L, et al.
**摘要**：文章利用抗CXCL6抗体阻断CXCL6与受体CXCR1/2的相互作用，证实CXCL6通过激活STAT3通路诱导结肠癌细胞迁移，抗体干预可减少肿瘤相关巨噬细胞的促癌效应。
3. **标题**：CXCL6 as a potential therapeutic target in inflammatory bowel disease
**作者**：Smith J, et al.
**摘要**：该研究在炎症性肠病模型中评估了抗CXCL6抗体的治疗效果，结果显示抗体可减轻肠道黏膜中性粒细胞浸润及组织损伤，提示CXCL6在炎症反应中的关键作用。
(注：以上文献为示例性概括，实际引用需通过PubMed等学术平台检索真实文献。)
CXCL6. a member of the CXC chemokine family (also known as granulocyte chemotactic protein-2. GCP-2), is a small secreted protein primarily produced by activated macrophages, endothelial cells, and fibroblasts. It plays a critical role in neutrophil recruitment, angiogenesis, and tissue repair by binding to the receptors CXCR1 and CXCR2. which activate downstream signaling pathways such as PI3K/AKT and MAPK. CXCL6 is implicated in inflammatory diseases (e.g., arthritis, atherosclerosis) and cancer progression, where it may promote tumor growth, metastasis, and immune evasion.
Antibodies targeting CXCL6 are essential tools for studying its expression, function, and regulatory mechanisms. These antibodies, including polyclonal and monoclonal variants, enable the detection of CXCL6 in biological samples via techniques like ELISA, Western blotting, immunohistochemistry, and flow cytometry. High-specificity CXCL6 antibodies help elucidate its dual roles in disease contexts—pro-inflammatory and pro-tumorigenic versus tissue-protective effects—and validate its potential as a therapeutic target. Neutralizing antibodies, in particular, are explored for blocking CXCL6-mediated pathways in inflammatory disorders or cancer. Commercial CXCL6 antibodies are typically validated for cross-reactivity across species (human, mouse, rat) and applications, ensuring reliability in preclinical research. Ongoing studies focus on optimizing antibody affinity and developing clinical-grade reagents to advance therapeutic strategies targeting the CXCL6-CXCR1/2 axis.
×
